Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
1. DNTH to announce Phase 2 MaGic trial results for claseprubart.
2. The call is scheduled for September 8, 2025, at 8:00 a.m. EDT.
3. Dianthus focuses on novel monoclonal antibodies for severe autoimmune diseases.
4. A replay of the call will be available post-event.
5. The trial's success could significantly impact DNTH's market position.
Positive outcomes from clinical trials often increase stock value, as seen in previous biopharma examples. If results are strong, it may lead to heightened investor interest and increased share price.
How important is it?
The Phase 2 trial results are critical for DNTH's future direction and investor confidence. Promising results could attract new investments and partnerships.
Why Short Term?
The upcoming announcement is imminent and will directly influence the stock price. Unexpected positive results could lead to immediate trading interest.
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.
Investor Webcast & Conference Call Information To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.
A live webcast may be accessed through the Investors and Media section of the Company's website, www.dianthustx.com. Following the call, a replay will be available at the same location.
About Dianthus Therapeutics Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
